- Department of Orthopedics/Orthopaedic Research Institute, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China;
ZENG Yi,
Email: zengyigd@126.com
Hip osteoarthritis (OA) is a significant disease worldwide that causes functional impairment and reduced quality of life. With the aging of the population and the increasing prevalence of obesity, its disease burden is becoming increasingly heavy. In December 2023, the American Academy of Orthopaedic Surgeons (AAOS) released the updated Clinical Practice Guideline for the Management of Hip Osteoarthritis. Based on evidence-based medicine, this guideline provides systematic recommendations for the diagnosis and treatment of hip OA. This article will comprehensively interpret the guideline, compare it with relevant domestic expert consensus in China, analyze the consistency and differences in disease management strategies between the two, and provide references for clinical practice.
Copyright © the editorial department of Chinese Journal of Reparative and Reconstructive Surgery of West China Medical Publisher. All rights reserved
| 1. | Fan Z, Yan L, Liu H, et al. The prevalence of hip osteoarthritis: a systematic review and meta-analysis. Arthritis Res Ther, 2023, 25(1): 51. doi: 10.1186/s13075-023-03033-7. |
| 2. | Reyes C, Leyland KM, Peat G, et al. Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: A population-based cohort study. Arthritis Rheumatol, 2016, 68(8): 1869-1875. |
| 3. | Maradit Kremers H, Larson DR, Crowson CS, et al. Prevalence of total hip and knee replacement in the United States J Bone Joint Surg (Am), 2015, 97(17): 1386-1397. |
| 4. | Eun Y, Yoo JE, Han K, et al. Female reproductive factors and risk of joint replacement arthroplasty of the knee and hip due to osteoarthritis in postmenopausal women: a nationwide cohort study of 1. 13 million women. Osteoarthritis Cartilage, 2022, 30(1): 69-80. |
| 5. | Stubbs B, Aluko Y, Myint PK, et al. Prevalence of depressive symptoms and anxiety in osteoarthritis: a systematic review and meta-analysis. Age Ageing, 2016, 45(2): 228-235. |
| 6. | Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the U. S. , 2014 to 2030. J Bone Joint Surg (Am), 2018, 100(17): 1455-1460. |
| 7. | da Costa BR, Pereira TV, Saadat P, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ, 2021, 375: n2321. doi: 10.1136/bmj.n2321. |
| 8. | 何方舟, 张伟滨. 非甾体类抗炎药对中国骨关节炎患者疗效及胃肠道不良反应的Meta分析. 中华关节外科杂志: 电子版, 2018, 12(1): 69-76. |
| 9. | Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthritis Cartilage, 2023, 31(4): 458-466. |
| 10. | Brophy RH, Fillingham YA. AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition. J Am Acad Orthop Surg, 2022, 30(9): e721-e729. |
| 11. | Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken), 2020, 72(2): 149-162. |
| 12. | Kloppenburg M, Kroon FP, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis, 2019, 78(1): 16-24. |
| 13. | Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum, 2019, 49(3): 337-350. |
| 14. | Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019, 27(11): 1578-1589. |
| 15. | Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken), 2012, 64(4): 465-474. |
| 16. | Hauk L. Treatment of knee osteoarthritis: a clinical practice guideline from the AAOS. Am Fam Physician, 2014, 89(11): 918-920. |
| 17. | McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage, 2014, 22(3): 363-388. |
| 18. | Jawad AS. EULAR recommendations for the management of knee osteoarthritis. Ann Rheum Dis, 2001, 60(5): 540. doi: 10.1136/ard.60.5.540. |
| 19. | Zywiel MG, Stroh DA, Lee SY, et al. Chronic opioid use prior to total knee arthroplasty. J Bone Joint Surg (Am), 2011, 93(21): 1988-1993. |
| 20. | Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step Ⅲ opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract, 2008, 8(4): 287-313. |
| 21. | Fisher DA, Dierckman B, Watts MR, et al. Looks good but feels bad: factors that contribute to poor results after total knee arthroplasty. J Arthroplasty, 2007, 22(6 Suppl 2): 39-42. |
| 22. | Franklin PD, Karbassi JA, Li W, et al. Reduction in narcotic use after primary total knee arthroplasty and association with patient pain relief and satisfaction. J Arthroplasty, 2010, 25(6 Suppl): 12-16. |
| 23. | Pivec R, Issa K, Naziri Q, et al. Opioid use prior to total hip arthroplasty leads to worse clinical outcomes. Int Orthop, 2014, 38(6): 1159-1165. |
| 24. | 冉金伟, 杨婧, 喻绍顶, 等. 阿片类药物治疗骨关节炎安全性的Meta分析. 广西医学, 2020, 42(6): 734-740+754. |
| 25. | Ruiz Iban MA, Benavides J, Forero JP, et al. Use of strong opioids for chronic pain in osteoarthritis: an insight into the Latin American reality. Expert Rev Clin Pharmacol, 2018, 11(1): 47-59. |
| 26. | Bruyère O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum, 2014, 44(3): 253-263. |
| 27. | Cheng OT, Souzdalnitski D, Vrooman B, et al. Evidence-based knee injections for the management of arthritis. Pain Med, 2012, 13(6): 740-753. |
| 28. | Lei T, Wang Y, Li M, Hua L. Clinical efficacy of multiple intra-articular injection for hip osteoarthritis. Bone Joint J, 2024, 106-B(6): 532-539. |
| 29. | Deyle GD, Allen CS, Allison SC, et al. Physical therapy versus glucocorticoid injection for osteoarthritis of the knee. N Engl J Med, 2020, 382(15): 1420-1429. |
| 30. | McAlindon TE, LaValley MP, Harvey WF, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: A randomized clinical trial. JAMA, 2017, 317(19): 1967-1975. |
| 31. | Zeng C, Lane NE, Hunter DJ, et al. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. Osteoarthritis Cartilage, 2019, 27(6): 855-862. |
| 32. | Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol, 2020, 72(2): 220-233. |
| 33. | 中国老年保健协会骨关节保护与健康分会, 国家骨科医学中心北京积水潭医院保膝联盟. 膝骨关节炎糖皮质激素注射应用专家共识. 实用骨科杂志, 2024, 30(10): 865-875. |
| 34. | Paskins Z, Bromley K, Lewis M, et al. Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anaesthetic injection in addition to advice and education for hip osteoarthritis (HIT trial): single blind, parallel group, three arm, randomised controlled trial. BMJ, 2022, 377: e068446. doi: 10.1136/bmj-2021-068446. |
| 35. | 中国骨关节炎诊疗指南专家组. 中国骨关节炎诊疗指南(2024版). 中华疼痛学杂志, 2024, 20(3): 323-338. |
| 36. | Cibulka MT, Bloom NJ, Enseki KR, et al. Hip pain and mobility deficits-hip osteoarthritis: Revision 2017. J Orthop Sports Phys Ther, 2017, 47(6): A1-A37. |
| 37. | Moseng T, Vliet Vlieland TPM, Battista S, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update. Ann Rheum Dis, 2024, 83(6): 730-740. |
| 38. | Ghorbani M, Sadrian SH, Ghaderpanah R, et al. Tranexamic acid in total hip arthroplasty: An umbrella review on efficacy and safety. J Orthop, 2024, 54: 90-102. |
| 39. | Grassin-Delyle S, Semeraro M, Lamy E, et al. Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. Br J Anaesth, 2022, 128(3): 465-472. |
| 40. | Sun X, Dong Q, Zhang YG. Intravenous versus topical tranexamic acid in primary total hip replacement: A systemic review and meta-analysis. Int J Surg, 32: 10-18. |
| 41. | Kuo FC, Lin PY, Wang JW, et al. Intravenous tranexamic acid use in revision total joint arthroplasty: a meta-analysis. Drug Des Devel Ther, 2018, 12: 3163-3170. |
| 42. | Hines JT, Hernandez NM, Amundson AW, et al. Intravenous tranexamic acid safely and effectively reduces transfusion rates in revision total hip arthroplasty. Bone Joint J, 2019, 101-B(6_Supple_B): 104-109. |
| 43. | Gianakos AL, Saad BN, Haring R, et al. Tranexamic acid lowers transfusion requirements and hospital length of stay following revision total hip or knee arthroplasty. Patient Saf Surg, 2021, 15(1): 21. doi: 10.1186/s13037-021-00295-5. |
| 44. | Bunyoz KI, Malchau E, Malchau H, et al. Has the use of fixation techniques in THA changed in this decade? The uncemented paradox revisited. Clin Orthop Relat Res, 2020, 478(4): 697-704. |
| 45. | 冮义. 骨水泥和非骨水泥型假体在骨质疏松症患者全髋关节置换术中的应用比较. 中国医疗器械信息, 2023, 29(6): 130-132. |
| 46. | 张庆, 李甲, 朱善邦, 等. 骨质疏松症患者全髋关节置换术假体选择: 骨水泥或非骨水泥型假体. 中华骨与关节外科杂志, 2020, 13(9): 788-792. |
| 47. | 广清青, 石磊. 生物型和骨水泥型股骨假体全髋关节置换术治疗老年骨质疏松性股骨颈骨折疗效比较. 临床合理用药杂志, 2019, 12(32): 148-149. |
| 48. | Graves SC, Dropkin BM, Keeney BJ, et al. Does surgical approach affect patient-reported function after primary THA? Clin Orthop Relat Res, 2016, 474(4): 971-981. |
| 49. | Yan L, Ge L, Dong S, et al. Evaluation of comparative efficacy and safety of surgical approaches for total hip arthroplasty: A systematic review and network meta-analysis. JAMA Netw Open, 2023, 6(1): e2253942. doi: 10.1001/jamanetworkopen.2022.53942. |
| 50. | Lygrisse KA, Gaukhman GD, Teo G, et al. Is surgical approach for primary total hip arthroplasty associated with timing, incidence, and characteristics of periprosthetic femur fractures? J Arthroplasty, 2021, 36(9): 3305-3311. |
| 51. | Pincus D, Jenkinson R, Paterson M, et al. Association between surgical approach and major surgical complications in patients undergoing total hip arthroplasty. JAMA, 2020, 323(11): 1070-1076. |
| 52. | Blizzard DJ, Penrose CT, Sheets CZ, et al. Ankylosing spondylitis increases perioperative and postoperative complications after total hip arthroplasty. J Arthroplasty, 2017, 32(8): 2474-2479. |
| 53. | Turcotte JJ, Stone AH, Gilmor RJ, et al. The effect of neuraxial anesthesia on postoperative outcomes in total joint arthroplasty with rapid recovery protocols. J Arthroplasty, 2020, 35(4): 950-954. |
| 54. | Kelly ME, Turcotte JJ, Aja JM, et al. General vs neuraxial anesthesia in direct anterior approach total hip arthroplasty: effect on length of stay and early pain control. J Arthroplasty, 2021, 36(3): 1013-1017. |
| 55. | Baldawi M, Awad ME, McKelvey G, et al. Neuraxial anesthesia significantly reduces 30-day venous thromboembolism rate and length of hospital stay in primary total hip arthroplasty: a stratified propensity score-matched cohort analysis. J Arthroplasty, 2023, 38(1): 108-116. |
| 56. | Cozowicz C, Poeran J, Zubizarreta N, et al. Trends in the use of regional anesthesia: neuraxial and peripheral nerve blocks. Reg Anesth Pain Med, 2016, 41(1): 43-49. |
| 57. | Illescas A, Cozowicz C, Zhong H, et al. Comparative effectiveness of neuraxial versus general anesthesia in total joint replacement surgery: an updated retrospective analysis using more recent data. Reg Anesth Pain Med, 2024. doi: 10.1136/rapm-2024-105438. |
| 58. | DeMik DE, Kohler JG, Carender CN, et al. What is the impact of body mass index cutoffs on total hip arthroplasty complications? J Arthroplasty, 2022, 37(7): 1320-1325. |
| 59. | Alvi HM, Mednick RE, Krishnan V, et al. The efect of BMI on 30 day outcomes following total joint arthroplasty. J Arthroplasty, 2015, 30(7): 1113-1117. |
| 60. | Harris AB, Wang KY, Reddy R, et al. A novel method for stratification of major complication risk using body mass index thresholds for patients undergoing total hip arthroplasty: a national cohort of 224, 413 patients. J Arthroplasty, 2022, 37(10): 2049-2052. |
| 61. | Ledford CK, Elstad ZM, Fruth KM, et al. The impact of metabolic syndrome on reoperations and complications after primary total hip arthroplasty. J Arthroplasty, 2022, 37(6): 1092-1097. |
| 62. | Maradit Kremers H, Schleck CD, Lewallen EA, et al. Diabetes mellitus and hyperglycemia and the risk of aseptic loosening in total joint arthroplasty. J Arthroplasty, 2017, 32(9S): S251-S253. |
| 63. | Kebaish KJ, Puvanesarajah V, Rao S, et al. Diabetes status affects odds of body mass index-dependent adverse outcomes after total hip arthroplasty. J Am Acad Orthop Surg, 2021, 29(2): 71-77. |
| 64. | Chandrupatla S, Rumalla K, Singh JA. Association between diabetes mellitus and total hip arthroplasty outcomes: an observational study using the US National Inpatient Sample. BMJ Open, 2024, 14(7): e085400. doi: 10.1136/bmjopen-2024-085400. |
| 65. | Wier J, Liu KC, Richardson MK, et al. Higher blood glucose levels on the day of surgery are associated with an increased risk of periprosthetic joint infection after total hip arthroplasty. J Bone Joint Surg (Am), 2024, 106(4): 276-287. |
- 1. Fan Z, Yan L, Liu H, et al. The prevalence of hip osteoarthritis: a systematic review and meta-analysis. Arthritis Res Ther, 2023, 25(1): 51. doi: 10.1186/s13075-023-03033-7.
- 2. Reyes C, Leyland KM, Peat G, et al. Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: A population-based cohort study. Arthritis Rheumatol, 2016, 68(8): 1869-1875.
- 3. Maradit Kremers H, Larson DR, Crowson CS, et al. Prevalence of total hip and knee replacement in the United States J Bone Joint Surg (Am), 2015, 97(17): 1386-1397.
- 4. Eun Y, Yoo JE, Han K, et al. Female reproductive factors and risk of joint replacement arthroplasty of the knee and hip due to osteoarthritis in postmenopausal women: a nationwide cohort study of 1. 13 million women. Osteoarthritis Cartilage, 2022, 30(1): 69-80.
- 5. Stubbs B, Aluko Y, Myint PK, et al. Prevalence of depressive symptoms and anxiety in osteoarthritis: a systematic review and meta-analysis. Age Ageing, 2016, 45(2): 228-235.
- 6. Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the U. S. , 2014 to 2030. J Bone Joint Surg (Am), 2018, 100(17): 1455-1460.
- 7. da Costa BR, Pereira TV, Saadat P, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ, 2021, 375: n2321. doi: 10.1136/bmj.n2321.
- 8. 何方舟, 张伟滨. 非甾体类抗炎药对中国骨关节炎患者疗效及胃肠道不良反应的Meta分析. 中华关节外科杂志: 电子版, 2018, 12(1): 69-76.
- 9. Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthritis Cartilage, 2023, 31(4): 458-466.
- 10. Brophy RH, Fillingham YA. AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition. J Am Acad Orthop Surg, 2022, 30(9): e721-e729.
- 11. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken), 2020, 72(2): 149-162.
- 12. Kloppenburg M, Kroon FP, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis, 2019, 78(1): 16-24.
- 13. Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum, 2019, 49(3): 337-350.
- 14. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019, 27(11): 1578-1589.
- 15. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken), 2012, 64(4): 465-474.
- 16. Hauk L. Treatment of knee osteoarthritis: a clinical practice guideline from the AAOS. Am Fam Physician, 2014, 89(11): 918-920.
- 17. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage, 2014, 22(3): 363-388.
- 18. Jawad AS. EULAR recommendations for the management of knee osteoarthritis. Ann Rheum Dis, 2001, 60(5): 540. doi: 10.1136/ard.60.5.540.
- 19. Zywiel MG, Stroh DA, Lee SY, et al. Chronic opioid use prior to total knee arthroplasty. J Bone Joint Surg (Am), 2011, 93(21): 1988-1993.
- 20. Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step Ⅲ opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract, 2008, 8(4): 287-313.
- 21. Fisher DA, Dierckman B, Watts MR, et al. Looks good but feels bad: factors that contribute to poor results after total knee arthroplasty. J Arthroplasty, 2007, 22(6 Suppl 2): 39-42.
- 22. Franklin PD, Karbassi JA, Li W, et al. Reduction in narcotic use after primary total knee arthroplasty and association with patient pain relief and satisfaction. J Arthroplasty, 2010, 25(6 Suppl): 12-16.
- 23. Pivec R, Issa K, Naziri Q, et al. Opioid use prior to total hip arthroplasty leads to worse clinical outcomes. Int Orthop, 2014, 38(6): 1159-1165.
- 24. 冉金伟, 杨婧, 喻绍顶, 等. 阿片类药物治疗骨关节炎安全性的Meta分析. 广西医学, 2020, 42(6): 734-740+754.
- 25. Ruiz Iban MA, Benavides J, Forero JP, et al. Use of strong opioids for chronic pain in osteoarthritis: an insight into the Latin American reality. Expert Rev Clin Pharmacol, 2018, 11(1): 47-59.
- 26. Bruyère O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum, 2014, 44(3): 253-263.
- 27. Cheng OT, Souzdalnitski D, Vrooman B, et al. Evidence-based knee injections for the management of arthritis. Pain Med, 2012, 13(6): 740-753.
- 28. Lei T, Wang Y, Li M, Hua L. Clinical efficacy of multiple intra-articular injection for hip osteoarthritis. Bone Joint J, 2024, 106-B(6): 532-539.
- 29. Deyle GD, Allen CS, Allison SC, et al. Physical therapy versus glucocorticoid injection for osteoarthritis of the knee. N Engl J Med, 2020, 382(15): 1420-1429.
- 30. McAlindon TE, LaValley MP, Harvey WF, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: A randomized clinical trial. JAMA, 2017, 317(19): 1967-1975.
- 31. Zeng C, Lane NE, Hunter DJ, et al. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. Osteoarthritis Cartilage, 2019, 27(6): 855-862.
- 32. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol, 2020, 72(2): 220-233.
- 33. 中国老年保健协会骨关节保护与健康分会, 国家骨科医学中心北京积水潭医院保膝联盟. 膝骨关节炎糖皮质激素注射应用专家共识. 实用骨科杂志, 2024, 30(10): 865-875.
- 34. Paskins Z, Bromley K, Lewis M, et al. Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anaesthetic injection in addition to advice and education for hip osteoarthritis (HIT trial): single blind, parallel group, three arm, randomised controlled trial. BMJ, 2022, 377: e068446. doi: 10.1136/bmj-2021-068446.
- 35. 中国骨关节炎诊疗指南专家组. 中国骨关节炎诊疗指南(2024版). 中华疼痛学杂志, 2024, 20(3): 323-338.
- 36. Cibulka MT, Bloom NJ, Enseki KR, et al. Hip pain and mobility deficits-hip osteoarthritis: Revision 2017. J Orthop Sports Phys Ther, 2017, 47(6): A1-A37.
- 37. Moseng T, Vliet Vlieland TPM, Battista S, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update. Ann Rheum Dis, 2024, 83(6): 730-740.
- 38. Ghorbani M, Sadrian SH, Ghaderpanah R, et al. Tranexamic acid in total hip arthroplasty: An umbrella review on efficacy and safety. J Orthop, 2024, 54: 90-102.
- 39. Grassin-Delyle S, Semeraro M, Lamy E, et al. Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. Br J Anaesth, 2022, 128(3): 465-472.
- 40. Sun X, Dong Q, Zhang YG. Intravenous versus topical tranexamic acid in primary total hip replacement: A systemic review and meta-analysis. Int J Surg, 32: 10-18.
- 41. Kuo FC, Lin PY, Wang JW, et al. Intravenous tranexamic acid use in revision total joint arthroplasty: a meta-analysis. Drug Des Devel Ther, 2018, 12: 3163-3170.
- 42. Hines JT, Hernandez NM, Amundson AW, et al. Intravenous tranexamic acid safely and effectively reduces transfusion rates in revision total hip arthroplasty. Bone Joint J, 2019, 101-B(6_Supple_B): 104-109.
- 43. Gianakos AL, Saad BN, Haring R, et al. Tranexamic acid lowers transfusion requirements and hospital length of stay following revision total hip or knee arthroplasty. Patient Saf Surg, 2021, 15(1): 21. doi: 10.1186/s13037-021-00295-5.
- 44. Bunyoz KI, Malchau E, Malchau H, et al. Has the use of fixation techniques in THA changed in this decade? The uncemented paradox revisited. Clin Orthop Relat Res, 2020, 478(4): 697-704.
- 45. 冮义. 骨水泥和非骨水泥型假体在骨质疏松症患者全髋关节置换术中的应用比较. 中国医疗器械信息, 2023, 29(6): 130-132.
- 46. 张庆, 李甲, 朱善邦, 等. 骨质疏松症患者全髋关节置换术假体选择: 骨水泥或非骨水泥型假体. 中华骨与关节外科杂志, 2020, 13(9): 788-792.
- 47. 广清青, 石磊. 生物型和骨水泥型股骨假体全髋关节置换术治疗老年骨质疏松性股骨颈骨折疗效比较. 临床合理用药杂志, 2019, 12(32): 148-149.
- 48. Graves SC, Dropkin BM, Keeney BJ, et al. Does surgical approach affect patient-reported function after primary THA? Clin Orthop Relat Res, 2016, 474(4): 971-981.
- 49. Yan L, Ge L, Dong S, et al. Evaluation of comparative efficacy and safety of surgical approaches for total hip arthroplasty: A systematic review and network meta-analysis. JAMA Netw Open, 2023, 6(1): e2253942. doi: 10.1001/jamanetworkopen.2022.53942.
- 50. Lygrisse KA, Gaukhman GD, Teo G, et al. Is surgical approach for primary total hip arthroplasty associated with timing, incidence, and characteristics of periprosthetic femur fractures? J Arthroplasty, 2021, 36(9): 3305-3311.
- 51. Pincus D, Jenkinson R, Paterson M, et al. Association between surgical approach and major surgical complications in patients undergoing total hip arthroplasty. JAMA, 2020, 323(11): 1070-1076.
- 52. Blizzard DJ, Penrose CT, Sheets CZ, et al. Ankylosing spondylitis increases perioperative and postoperative complications after total hip arthroplasty. J Arthroplasty, 2017, 32(8): 2474-2479.
- 53. Turcotte JJ, Stone AH, Gilmor RJ, et al. The effect of neuraxial anesthesia on postoperative outcomes in total joint arthroplasty with rapid recovery protocols. J Arthroplasty, 2020, 35(4): 950-954.
- 54. Kelly ME, Turcotte JJ, Aja JM, et al. General vs neuraxial anesthesia in direct anterior approach total hip arthroplasty: effect on length of stay and early pain control. J Arthroplasty, 2021, 36(3): 1013-1017.
- 55. Baldawi M, Awad ME, McKelvey G, et al. Neuraxial anesthesia significantly reduces 30-day venous thromboembolism rate and length of hospital stay in primary total hip arthroplasty: a stratified propensity score-matched cohort analysis. J Arthroplasty, 2023, 38(1): 108-116.
- 56. Cozowicz C, Poeran J, Zubizarreta N, et al. Trends in the use of regional anesthesia: neuraxial and peripheral nerve blocks. Reg Anesth Pain Med, 2016, 41(1): 43-49.
- 57. Illescas A, Cozowicz C, Zhong H, et al. Comparative effectiveness of neuraxial versus general anesthesia in total joint replacement surgery: an updated retrospective analysis using more recent data. Reg Anesth Pain Med, 2024. doi: 10.1136/rapm-2024-105438.
- 58. DeMik DE, Kohler JG, Carender CN, et al. What is the impact of body mass index cutoffs on total hip arthroplasty complications? J Arthroplasty, 2022, 37(7): 1320-1325.
- 59. Alvi HM, Mednick RE, Krishnan V, et al. The efect of BMI on 30 day outcomes following total joint arthroplasty. J Arthroplasty, 2015, 30(7): 1113-1117.
- 60. Harris AB, Wang KY, Reddy R, et al. A novel method for stratification of major complication risk using body mass index thresholds for patients undergoing total hip arthroplasty: a national cohort of 224, 413 patients. J Arthroplasty, 2022, 37(10): 2049-2052.
- 61. Ledford CK, Elstad ZM, Fruth KM, et al. The impact of metabolic syndrome on reoperations and complications after primary total hip arthroplasty. J Arthroplasty, 2022, 37(6): 1092-1097.
- 62. Maradit Kremers H, Schleck CD, Lewallen EA, et al. Diabetes mellitus and hyperglycemia and the risk of aseptic loosening in total joint arthroplasty. J Arthroplasty, 2017, 32(9S): S251-S253.
- 63. Kebaish KJ, Puvanesarajah V, Rao S, et al. Diabetes status affects odds of body mass index-dependent adverse outcomes after total hip arthroplasty. J Am Acad Orthop Surg, 2021, 29(2): 71-77.
- 64. Chandrupatla S, Rumalla K, Singh JA. Association between diabetes mellitus and total hip arthroplasty outcomes: an observational study using the US National Inpatient Sample. BMJ Open, 2024, 14(7): e085400. doi: 10.1136/bmjopen-2024-085400.
- 65. Wier J, Liu KC, Richardson MK, et al. Higher blood glucose levels on the day of surgery are associated with an increased risk of periprosthetic joint infection after total hip arthroplasty. J Bone Joint Surg (Am), 2024, 106(4): 276-287.